Table 3.

Cost-effectiveness for expanded HPV Vaccination: incremental increase of upper age limit of expanded catch-up^a.

Strategy	Treatment costs ($)	Screening costs ($)	Vaccine costs ($)	Total costs ($)	Total QALYs (QALY)	ICER ($/QALY)
Status quob	287.83	1,003.43	140.57	1,431.83	27.6097625	–
Expanded catch-up for 13–26 year-olds	286.60	1,003.42	146.68	1,436.70	27.6098038	Weakly Dominated ($117,000c)
Expanded catch-up for 13–29 year-olds	285.37	1,003.41	152.07	1,440.85	27.6098501	103,000d
Expanded catch-up for 13–34 year-olds	283.21	1,003.38	162.70	1,449.29	27.6099291	107,000e
Expanded catch-up for 13–39 year-olds	281.42	1,003.35	174.47	1,459.24	27.6099926	157,000f
Expanded catch-up for 13–45 year-olds	280.15	1,003.34	187.00	1,470.49	27.6100365	256,000g

^aCosts and QALYs are per capita accumulated over a 100-year time horizon with 3% annual discount rate.

^bStatus quo includes vaccination of 9–26 year females, and 9–21 year males

^cThe ICER of current ACIP recommendations (harmonization) compared with status quo is $117,000/QALY

^dICER for expanded catch-up for 13–29 years, compared with status quo

^eICER for expanded catch-up for 13–34 years, compared with vaccinating 13–29 years

^fICER for expanded catch-up for 13–39 years, compared with vaccinating 13–34 years

^gICER for expanded catch-up for 13–45 years, compared with vaccinating 13–39 years

Abbreviations: ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life years